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Porcine reproductive and respiratory syndrome (PRRS) is one of the most challenging subjects of research in veterinary viral immunol-
ogy, and the immune response against PRRS virus (PRRSV) still is poorly understood. Infected pigs develop a strong and rapid humoral
response but these initial antibodies do not confer protection and can even be harmful by mediating an antibody-dependent enhancement
of disease. In contrast, development of neutralising antibodies (NAs) is delayed and generation of cell-mediated immune responses, such as
PRRSV-specific interferon (IFN)-c secreting cells, is initially erratic. In spite of this, induction of strong and rapid NAs and IFN-c
responses seem to be required for effective vaccination. PRRSV strongly modulates the host’s immune responses. The virus inhibits key
cytokines, such as IFN-a, and may induce regulatory cytokines, such as interleukin (IL)-10. Development of NAs seems to be impaired
by the existence of a decoy epitope close to the main neutralisation epitope in glycoprotein 5. This ability to modulate the host immune
response probably varies among strains or isolates. The genetic diversity of the virus is very high and it has been shown that this diversity
can have serious implications for the development of vaccines, since the immunity induced by one strain may be only partial against a dif-
ferent strain, even within the same genotype. With this panorama, the development of newer and universally efficacious PRRSV vaccines is
challenging, but the present state of knowledge allows optimism if collaborative efforts are undertaken in the scientific community.
 2007 Elsevier Ltd. All rights reserved.
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More than 15 years after the emergence of porcine repro-
ductive and respiratory syndrome (PRRS), our understand-
ing of the disease still is far from complete. The clinical
features of PRRS are well known, a global picture of the
epidemiology has been drawn, although some gaps remain
to be filled, management and husbandry procedures have
been devised for controlling the disease and vaccines are
available. However, infection by PRRS virus (PRRSV) is
still widespread and the virus is frequently reintroduced to
farms after eradication. What are the reasons for such fail-
ures? The answer is not simple, but examination of the sci-
entific literature and problems reported by pig veterinarians
indicates that vaccines can be a useful tool, although their1090-0233/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail address: enric.mateu@uab.es (E. Mateu).efficacy is far from being universal and complete. The
approach of ‘‘let’s take a strain, let’s attenuate or inactivate
it and, voila`! the vaccine will generate sufficient immunity to
protect against the disease’’ is not valid for PRRSV.
The present review discusses what is known and what
gaps remain in our understanding of PRRSV immunity
and its immunopathogenesis. It concludes with the positive
message that currently available information should allow
us to identify the crucial points that need to be studied in
order to understand the disease and overcome the chal-
lenge of PRRSV immunology.
Adaptive immune response to PRRSV
Humoral immunity
The development of adaptive immunity against
PRRSV is a tale of unusual features in both the humoral
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lating antibodies against PRRSV are detectable in some
pigs by days 5–7 post-infection (PI) and all animals have
seroconverted by day 14 PI (Yoon et al., 1992,1995).
PRRSV-specific immunoglobulin M (IgM) reaches a peak
at day 14 PI and then declines to undetectable levels by 42
days PI. Concentrations of IgG reach a maximum at 21–
49 days PI (Vezina et al., 1996; Loemba et al., 1996).
However, this rapid IgM and IgG response does not cor-
respond to neutralising antibodies (NAs) (Yoon et al.,
1994).
Nelson et al. (1994) studied the kinetics of the humoral
response of pigs against an American strain of PRRSV.
The earliest antibodies were directed against the 15 KDa
nucleoprotein, followed by the 19 KDa M protein, then
the 26 KDa glycoprotein 5 (GP5). Other studies showed
that non-structural protein 2 (nsp2) contains a cluster of
non-neutralising B-epitopes and probably is the immuno-
dominant protein of PRRSV (Oleksiewicz et al., 2001; de
Lima et al., 2006). Most diagnostic tests detect antibodies
mainly against the N protein. These antibodies appear
around the first week PI and persist for several months,
but do not correlate with protection.
NAs are not detected by conventional virus neutralisa-
tion tests (VNTs) in the first 4 weeks PI. Addition of fresh
complement and prolonged incubation of virus–serum mix-
tures increases the sensitivity of the VNT and allows detec-
tion of NAs earlier (days 9–12 PI) (Takikawa et al., 1996).
Other authors showed that complement may increase VNT
titres by one dilution (Diaz et al., 2005, 2006). Since the
addition of 2-mercaptoethanol significantly reduced the
sensitivity of the modified VNT, it is likely that low levels
of neutralising IgM appear in the early phases of the infec-
tion (Takikawa et al., 1996). However, even with this mod-
ified VNT, NA titres were still relatively low (1/32–1/64) by
day 42 PI.
NAs are consistently detected by day 28 PI or later for
both European and American-type strains of PRRSV
(Yoon et al., 1994; Meier et al., 2003; Diaz et al., 2005).
These NAs are mainly directed against GP5, which con-
tains the major neutralisation epitope (Nelson et al.,
1994; Pirzadeh and Dea, 1997, 1998; Gonin et al., 1999).
It has been claimed that GP4 and M proteins also contain
neutralising epitopes (Meulenberg et al., 1997; Gonin et al.,
1999; Weiland et al., 1999; Yang et al., 2000; Cancel-Tirado
et al., 2004) and one report suggested that GP3 also con-
tains a neutralising epitope (Cancel-Tirado et al., 2004).
However, these proteins seem to be of minor biological sig-
nificance compared to GP5.
The early development of non-NAs may have a signif-
icant effect on the development of PRRS. It has been
shown that non-NAs enhance viral replication in alveo-
lar macrophages, a phenomenon known as antibody-
dependent enhancement (ADE) (Yoon et al., 1996,
1997). Targets for these antibodies are GP5 and N pro-
teins (Yoon et al., 1996; Cancel-Tirado et al., 2004). The
non-neutralising humoral response may act as a Trojanhorse for PRRSV by coating the virus and enhancing
the internalisation of viral particles into macrophages.
The question is: why NAs do not develop as early as
non-NAs?
NAs may play an important role, although their
importance may be different in natural infection com-
pared to vaccination. Vezina et al. (1996) reported the iso-
lation of PRRSV from the blood of pigs with NAs.
Following experimental infection, viraemia may be
resolved without detectable levels of neutralising antibod-
ies (Diaz et al., 2006). Similar to the related virus lactate
dehydrogenase virus (LDV), the dynamics of PRRSV-sus-
ceptible macrophages may govern the levels of viraemia
(Diaz et al., 2006). If cytolysis or apoptosis exhaust most
susceptible macrophages, infection will be confined to
macrophage-rich organs, such as lymph nodes. In this
hypothesis, NAs may be required for resolution of vira-
emia, if not infection.
A different picture arises when protection before infec-
tion is considered. NAs block PRRSV infectivity for mac-
rophages in vitro (Delputte et al., 2004). Transfer of NAs
to pregnant sows (NA titres 1/16) protects them against
reproductive failure and blocks transplacental infection
(Osorio et al., 2002). Using the same antibody transfer sys-
tem, a titre of 1/8 or higher protected piglets against the
development of viraemia, whereas sterilising immunity
was attained at NA titres of 1/32 (Lopez et al., 2007). These
results suggest that a vaccine capable of inducing NA titres
of 1/32 should prevent clinical disease and be a key tool in
eradication of PRRSV.
Cell-mediated immunity
Cell-mediated immunity (CMI) is also extremely impor-
tant in PRRS. Early studies showed that pigs recovering
from experimental PRRSV infection had strong lympho-
cyte proliferative responses, although these responses were
not detected until four weeks PI and paralleled the NA
response (Bautista and Molitor, 1997; Lopez Fuertes
et al., 1999). Cytokine responses were mainly interferon
(IFN)-c and, to a lesser extent, IL-2 (Lopez Fuertes
et al., 1999).
After vaccination with a modified live vaccine using an
American strain of PRRSV, virus-specific IFN-c secreting
cells first appeared in the third week post-vaccination, fluc-
tuated erratically from 50–100 per million peripheral blood
mononuclear cells (PBMCs) for the next ten weeks, then
increased to 400–500 per million PBMCs at 48 weeks
post-vaccination (Meier et al., 2003). IFN-c secreting cells
were mainly CD4+CD8+ cells, with a small proportion of
CD4/CD8ab+ cytotoxic T cells. A similar delayed devel-
opment of PRRSV-specific IFN-c secreting cells was evi-
dent after infection or vaccination with European strains
of PRRSV (Diaz et al., 2005,2006). In contrast, 200–300
IFN-c secreting cells per million PBMCs were evident by
3 weeks after vaccination against Aujeszky’s disease virus
(Meier et al., 2003).
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Interferons
The unusual characteristics of the adaptive immune
response to PRRSV suggest that the virus strongly modu-
lates the immune response. Early studies showed that
PRRSV is highly susceptible to the action of type I IFNs
and suggested that the virus was able to inhibit IFN-a
responses, since this cytokine could not be detected in the
lungs of pigs in which PRRSV was actively replicating
(Albina et al., 1998; Buddaert et al., 1998). IFN-a levels
in the lungs of PRRSV-infected pigs were much lower than
in the lungs of pigs infected with porcine coronavirus or
swine influenza virus (van Reeth et al., 1999). Frequencies
of virus-specific IFN-c secreting cells were correlated with
the frequencies of IFN-a secreting cells in pigs infected with
PRRSV (Royaee et al., 2004). Although the exact mecha-
nism by which PRRSV inhibits IFN-a is unknown, it does
not involve inhibition of the nuclear factor (NF)-j B path-
way (Lee and Kleiboeker, 2005).
Different PRRSV isolates and different plaque clones of
the same strain have different abilities to induce or inhibit
IFN-a (Lee et al., 2004). Preliminary results indicate that
different European PRRSV isolates have different abilities
to induce not only IFN-a, but also TNF-a, IL-10 and
IL-12, in alveolar macrophages and dendritic cells (unpub-
lished observations). Impairment of IFN-a secretion would
be expected to affect the development of an effective T
helper type 1 (Th1) immune response.
Cytokines
IL-10 may have an important role in the regulation of
the immune response to PRRSV. After infection with
either European or American strains of PRRSV, levels of
IL-10 mRNA were increased in porcine PBMCs (Suradhat
and Thanawongnuwech, 2003; Suradhat et al., 2003) and
concentrations of IL-10 were increased in bronchoalveolar
lavage (BAL) fluid (Thanawongnuwech et al., 2004). Some
European strains of PRRSV induce strong IL-10 responses
in PBMCs from naı¨ve pigs, suggesting that this is a not a
memory feature (Diaz et al., 2006). Pigs vaccinated with
IL-10-inducing strains had lower frequencies of PRRSV-
specific IFN-c secreting cells than animals vaccinated with
a non-IL-10 inducing strain (Diaz et al., 2006). Monocytes
appear to be the major source of IL-10 in PRRSV infection
(Charerntantanakul et al., 2006). PRRSV also appears to
induce IL-6 (Asai et al., 1999; Sipos et al., 2003), whereas
the role of transforming growth factor-b in PRRSV infec-
tion is unclear (Royaee et al., 2004).
Antigen presentation
PRRSV may interfere with correct antigen presentation
and activation of T lymphocytes. PRRSV down-regulated
expression of major histocompatibility complex (MHC)-Iin dendritic cells (DCs), although this was not correlated
with impaired proliferative responses in the mixed leuco-
cyte reaction (Loving et al., 2007). Expression of MHC-I
and MHC-II, as well as CD14, was down-regulated in
monocyte-derived DCs stimulated by infectious but not
inactivated PRRSV (Wang et al., 2007). In this study, pro-
liferative responses were decreased when infected DCs were
used with syngeneic or allogeneic lymphocytes, suggesting
that infected DCs present antigens less efficiently (Wang
et al., 2007). PRRSV may down-regulate the innate
immune response by altering the cytokine patterns of mac-
rophages and dendritic cells, as well as by modifying the
expression of molecules involved in antigen presentation.
Humoral immunity
As discussed previously, one of the intriguing features of
PRRSV infection is the delayed development of NAs. The
main neutralisation epitope of PRRSV, designated epitope
B, is located in the N-terminal ectodomain of GP5 (amino
acids 37–44) in both American and European strains
(Ostrowski et al., 2002; Plagemann et al., 2002; Wissink
et al., 2003; Plagemann, 2004). This neutralisation epitope
is flanked by glycosylation sites.
An additional immunodominant epitope, designated
epitope A, is located in the N-terminal ectodomain of
GP5 (amino acids 27 and 31) and has the characteristics
of a decoy epitope, similar to that in human immunodefi-
ciency virus type 1 (Ostrowski et al., 2002). The decoy epi-
tope may interfere with the immune response to the main
neutralisation epitope B, resulting in a delay in the NA
response. Insertion of a pan-DR helper T cell epitope
between the epitope B and the decoy epitope increased
the immunogenicity of epitope B in mice (Fang et al.,
2006), suggesting that the proximity of epitopes A and B
is important in delaying the NA response.
The decoy epitope is not the only way by which PRRSV
can evade the humoral immune response. GP5, the main
target for NAs, contains up to four glycosylation sites,
located in or close to the neutralising epitope. American
field strains of PRRSV lacking glycosylation sites in the
upstream hypervariable region induced NAs more rapidly
and more strongly in infected pigs than strains lacking the
downstream glycosylation site at position 44 (N-44), even
though all strains were equally susceptible to NAs (Faaberg
et al., 2006). As Spanish PRRSV strains have evolved from
1991–2005, there has been a trend to lose the glycosylation
site at N-46 (equivalent to N-44 of American strains) and to
maintain or gain glycosylations in the flanking regions (N-
37 and N-53), consistent with selection of strains inducing
weaker NA responses (Mateu et al., 2006).
Genetic diversity of PRRSV and implications for vaccine
development
PRRSV is divided into European (type I) and American
(type II) genotypes; four subtypes have been identified
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Diversity within a genotype or subtype can be high (Fors-
berg et al., 2002; Stadejek et al., 2002; Larochelle et al.,
2003; Mateu et al., 2003; Stadejek et al., 2006). Further-
more, PRRSV also demonstrates the phenomenon of
quasispecies generation (Rowland et al., 1999; Goldberg
et al., 2003). What is the impact of this genetic diversity
of PRRSV upon the immune response and protection
afforded by vaccination?
PRRS emerged in Europe and America almost simulta-
neously. The first vaccine against PRRSV marketed inter-
nationally was a modified live vaccine derived from the
prototypic American strain VR-2332. At that time, it was
obvious that the genetic diversity of PRRSV could pose
problems regarding the efficacy of the vaccine, particularly
with infections by the European genotype.
Pregnant gilts infected with the American isolate
NADC-8 and challenged with the European isolate Lelys-
tad virus (LV) late in gestation had only partial protection
against transplacental infection (virus crossed the placenta
in 1/7 gilts), whereas all gilts challenged with the homolo-
gous virus were fully protected (Lager et al., 1999). These
results showed that heterologous protection existed, but
was only partial, and suggested that common epitopes
are likely to be involved in protection in both European
and American-type strains.
Furthermore, monoclonal antibodies against the neu-
tralising epitope of the related virus LDV are able to neu-
tralise both VR-2332 and LV, indicating that the
neutralising epitope in GP5 is shared to some extent by
diverse arteriviruses (Plagemann et al., 2002) Although
partial heterologous protection might be beneficial under
some circumstances, a genotype-based vaccine is insuffi-
cient to produce immunising sterility.
Given the genetic diversity of the virus within one geno-
type, the question then was whether this phenomenon
might influence the efficacy of a homologous vaccine. Pig-
lets vaccinated with attenuated versions of American
strains NADC-8, 9 or 14 were challenged 21 days later with
a mixture of the virulent versions of the same strains (Men-
geling et al., 2003). A given virulent strain was not present
after challenge if the piglets had previously received the
attenuated version of that strain, whereas infections with
the other virulent strains were established, indicating that
immunity to PRRSV may be strain-related. After vaccina-
tion with a European-type modified live vaccine, pigs were
mostly negative for virus in serum or BAL fluid after chal-
lenge with LV (Labarque et al., 2004) In contrast, vacci-
nated pigs developed viraemia over 15 days and were
positive for virus in BAL fluid when challenged with an
Italian variant strain that had 84% similarity in ORF5 to
the vaccine strain.
Protection against PRRSV infection by a strain different
to the one used as a vaccine is somewhat more complex
than a matter of genetic similarity. Pigs were vaccinated
with two different European-type vaccines (v1 and v3),
then challenged with a strain similar to one of the vaccinesand slightly different to the other (92–96% similarity) (Diaz
et al., 2006). Surprisingly, the ‘‘heterologous’’ v3 vaccine
afforded sterilising immunity, while the homologous v1
vaccine did not. The v3 vaccine induced higher levels of
IFN-c secreting cells, whereas v1 induced IL-10 release
by PMBCs. The ability of each strain to induce a strong
cell-mediated immune response was more important that
the genetic similarity inducing protection.
Prospects for the development of universal PRRSV vaccines
The complexity of the immune response to PRRSV and
the ability of the virus to escape or modulate the host’s
immune system make it difficult to develop a vaccine that
can be used to eradicate the disease. Such a vaccine should
accomplish at least four requirements: efficacy, universal-
ity, safety and ability to differentiate vaccinated from
infected animals. The first line of investigation is the
detailed investigation of B and T cell epitopes involved in
the development of protective immunity. Neutralising epi-
topes have been established definitively. Little is known
regarding T cell epitopes, although T cell responses to indi-
vidual PRRSV polypeptides have been reported in virus-
infected animals (Bautista et al., 1999). Common critical
epitopes in both European and American strains of
PRRSV have to be clearly identified to support the devel-
opment of universal vaccines.
The second line of research is to determine which com-
ponents of the virion or viral genome are involved in the
down-regulation or modulation of the host’s immune sys-
tem and the mechanisms by which this occurs. This is crit-
ical for development of a live attenuated vaccine. The
efficacy of a given vaccine is not only related to its immu-
nological properties, but also to the characteristics of the
challenging strain. Therefore, studies on the relationship
between genetic diversity and the immunopathological
properties of different strains are needed. Reverse genetics
and characterisation of the modulating properties of an
extensive set of strains are necessary; this can only be
achieved through a serious international collaborative
effort.
Thirdly, the developed vaccine should be safe. This
means that any possibility of reversion to virulence should
be eliminated and transmission of the vaccine strain
between pigs should be minimal or non-existent. One obvi-
ous way to gain in safety is by using non-replicating vac-
cines. However, it is unclear if non-replicating vaccines
are able to induce NAs and adequate cell-mediated
immune responses (Zuckermann et al., 2007). Research
on subunit or vector-based vaccines and adjuvants should
be undertaken.
Fourthly, the development of a differential vaccine is
highly desirable. Since PRRSV is a virus with a relatively
small genome, it is difficult to find targets for deletion,
although, to our knowledge, an extensive study of essential
and non-essential parts of the viral genome has not been
performed. The occurrence of natural variants with small
Table 1
Some of the known, assumed and unknown features of the immune response in PRRSV infection relevant to the development of vaccines
Known Assumed/Supposed Unknown yet
Neutralising
antibodies
(NA)
GP5, GP4 M, GP3 (?)
Role of NA in
protection
Passive transfer protects against challenge Exact role of neutralising antibodies in
natural infection
Critical T cell
epitopes
T cell responses to individual PRRSV
polypeptides have been reported
Several viral proteins contain T cell
epitopes
Full set of critical epitopes
Cell-mediated
immunity
Frequencies of IFN-c secreting cells correlate
with protection against developing viraemia in
piglets in a challenge model
IFN-c may mediate sterilising
immunity
Precise requirement of IFN-c secreting
cells for protection
Viral immune
modulation
PRRSV contains a decoy epitope in GP5 The decoy epitope delays development
of neutralising antibodies
Viral proteins or mechanisms by which
IFN-a is inhibited or IL-10 induced
Certain PRRSV strains may inhibit IFN-a Lack of IFN-a and release of IL-10
may delay cell-mediated responsesCertain PRRSV strains may induce IL-10 release
Genetic
diversity
High genetic diversity within each genotype Genetic diversity might be related to
the immunopathological
characteristics of PRRSV strains
How genetic diversity correlates with
virulence or immunological properties
of PRRSV strains
Genetic diversity affects vaccine efficacy
Essential and
non-
essential
proteins
Structural proteins seem to be mainly essential Some non-structural proteins might be
non-essential
Exact map of essential and non-
essential proteinsSome of the non-structural proteins may suffer
natural deletions
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could be a target for constructing differential vaccines
(Fang et al., 2004).
It is necessary to demonstrate that a vaccine protects
against infection, not only in challenge experiments against
one strain of the same or a different genotype, but also
against different strains within a given genotype. Table 1
summarises some of the knowledge already known or
required for developing newer vaccines.Conclusions
The number of important questions that remain to be
solved in PRRS immunology is considerable. For example,
the development of the adaptive immune response after
infection with PRRSV or vaccination is anomalous. IFN-
c secreting cells appear late and evolve erratically during
the first weeks after infection; NA responses are also
delayed. NAs may protect against disease if present in suf-
ficient quantities before infection, but they do not seem to
be essential for clearing virus in blood during the course of
the infection. PRRSV is able to modulate innate responses,
probably through the regulation of IFN-a and IL-10
responses. Two different PRRSV genotypes exist that have
evolved in parallel. Cross protection afforded by each geno-
type is only partial and genetic diversity within each geno-
type can be high enough to allow a vaccinated animal to be
re-infected by a different strain of the same genotype. These
circumstances create difficulty in understanding how the
immune system and the virus interact.
It is possible that different PRRSV strains are able to
modulate or regulate the immune system in different ways.
Therefore, published experiments should be always inter-
preted with caution, particularly when trying to extractgeneral principles from a particular experiment. Collabora-
tion between researchers is the best way to enhance our
understanding of PRRSV immunology.
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